Glucagon-like peptide (GLP)-1-based therapy, which includes dipeptidyl peptidase (DPP)-4 inhibitors and GLP-1 receptor agonists, has become a popular treatment for patients with T2DM. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.